Week In Review: Hengrui Out-Licenses Novel Anti-Inflammatory To One Bio In $1 Billion Deal

Biosensor Technology Concepts. New Experiences with Metaverse, Web3 and Blockchain. Hand Interacting with the Computer Graphic Surrealism Butterfly via Biosensor Tech

BlackSalmon/iStock via Getty Images

Deals and Financings

Jiangsu Hengrui Pharma (SHA: 600275) out-licensed global rights (ex-China) for a novel anti-inflammatory to ONE Bio (OTC:ONBI) of Florida in a $1 billion deal (see story). SHR-1905 is an anti-TSLP

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *